Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Adjuvant Sacituzumab Govitecan Plus Nivolumab in Patients With Muscle-Invasive Urothelial Carcinoma at High-Risk for Recurrence

NCT06682728 is registered in ClinicalTrials.gov with University of California, Irvine as lead sponsor.

NCT NCT06682728
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06682728 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Adjuvant Sacituzumab Govitecan Plus Nivolumab in Patients With Muscle-Invasive Urothelial Carcinoma at High-Risk for Recurrence
Lead sponsor
University of California, Irvine
Phase
Phase 2
Overall status
Recruiting
Start date
November 15, 2024
Completion date
December 1, 2026
Enrollment
23 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

muscle-invasive bladder cancer, urothelial carcinoma